Eisai continues to experience growth in the United States, where we are headquartered in Woodcliff Lake, New Jersey. In addition to our headquarters operation, we also house commercial and clinical development organizations at this site.
This location is supported by two global demand chain organizations in Baltimore, Maryland and Raleigh, North Carolina. We also operate two Eisai discovery labs, one in Exton, Pennsylvania and in Andover, Massachusetts.
The Eisai Andover innovative Medicines (AiM) Institute is an industry-unique commitment to realize a new paradigm in human biology driven drug discovery. Here, approximately 90 quantitative, biological, chemistry and translational scientists work together to establish a discovery portfolio focused on precision medicine therapeutics for immuno-dementia, immuno-oncology, and auto-immune indications. The AiM Institute combines the focus, agility, and innovative culture of a biotech-like organization concentrated on executing novel therapeutic targets sufficiently validated by human genetics and other related sources of human biology data.